Page 90 - 16_Atti_SNO_2022_flip

Proceedings SNO “LXI Congresso Nazionale SNO”

liquor consentono lo studio di proteine, soprattutto amiloi- 4. Fantoni E, Collij L, Lopes Alves I, Buckley C, Farrar G;
de e Tau, ma le tecniche di neuro immagine hanno il van- AMYPAD consortium. The spatial-temporal ordering of amy-
taggio non solo di dimostrare determinate alterazioni, ma loid pathology and opportunities for PET imaging. J Nucl
anche dove esse sono allocate e, di fatto, mappare l’entità Med 2020; 61 (2): 166-171.
della patologia. Attualmente, l’orientamento clinico di arri- 5. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner
vare a una diagnosi sempre più precoce comporta che l’i- MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD,
Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ.
maging molecolare PET sia impiegato per capire se un pa-
Tracking pathophysiological processes in Alzheimer’s dis-
ziente con MCI (mild cognitive impairment) è nel cosid- ease: an updated hypothetical model of dynamic biomarkers.
detto “Alzheimer continuum” o se trattasi di una forma de-
Lancet Neurol 2013; 12 (2): 207-216.
generativa primaria, piuttosto che secondaria.
6. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B,
❒ ❒ CONCLUSIONI. L’imaging molecolare PET eseguito con
Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish
il corretto radiofarmaco per quel paziente o per assolvere
J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP,
quel quesito è un esame in grado di fornire elementi pre- Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R;
ziosi per il clinico non solo per la diagnosi, ma, nel pano- Contributors. NIA-AA Research Framework: Toward a bio-
rama della crescente ricerca di terapie mirate, di predirne o logical definition of Alzheimer’s disease. Alzheimers Dement
no la risposta. 2018; 14 (4): 535-562.
7. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack
CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ,
BIBLIOGRAFIA Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P,
Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis
1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, of dementia due to Alzheimer’s disease: recommendations
Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, from the National Institute on Aging-Alzheimer’s Association
Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of workgroups on diagnostic guidelines for Alzheimer’s disease.
mild cognitive impairment due to Alzheimer’s disease: recom-
Alzheimers Dement 2011; 7 (3): 263-269.
mendations from the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for 8. Minoshima S, Mosci K, Cross D, Thientunyakit T. Brain [F-
Alzheimer’s disease. Alzheimers Dement 2011; 7 (3): 270-279. 18]FDG PET for Clinical Dementia Workup: differential di-
agnosis of Alzheimer’s disease and other types of dementing
2. Boccardi M, Nicolosi V, Festari C, Bianchetti A, Cappa S, disorders. Semin Nucl Med 2021; 51 (3): 230-240.
Chiasserini D, Falini A, Guerra UP, Nobili F, Padovani A,
Sancesario G, Morbelli S, Parnetti L, Tiraboschi P, Muscio C, 9. Narayanan L, Murray AD. What can imaging tell us about
Perani D, Pizzini FB, Beltramello A, Salvini Porro G, Ciaccio cognitive impairment and dementia? World J Radiol 2016; 8
M, Schillaci O, Trabucchi M, Tagliavini F, Frisoni GB. Italian (3): 240-254.
consensus recommendations for a biomarker-based aetiologi- 10. Nobili F, Arbizu J, Bouwman F, Drzezga A, Agosta F, Nestor P,
cal diagnosis in mild cognitive impairment patients. Eur J Walker Z, Boccardi M; EANM-EAN Task Force for the
Neurol 2020; 27 (3): 475-483. Prescription of FDG-PET for Dementing Neurodegenerative
3. Chandra A, Valkimadi PE, Pagano G, Cousins O, Dervenoulas Disorders. European Association of Nuclear Medicine and
G, Politis M; Alzheimer’s Disease Neuroimaging Initiative. European Academy of Neurology recommendations for the use
Applications of amyloid, tau, and neuroinflammation PET im- of brain 18 F-fluorodeoxyglucose positron emission tomogra-
aging to Alzheimer’s disease and mild cognitive impairment. phy in neurodegenerative cognitive impairment and dementia:
Hum Brain Mapp 2019; 40 (18): 5424-5442. Delphi consensus. Eur J Neurol 2018; 25 (10): 1201-1217.

- 88 -